<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2016-6-4-21-29</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-549</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ЛЕКЦИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>LECTURES</subject></subj-group></article-categories><title-group><article-title>АЛЬДОСТЕРОН И ОЖИРЕНИЕ: ГДЕ ИСКАТЬ КЛЮЧ К ТЕРАПИИ?</article-title><trans-title-group xml:lang="en"><trans-title>ALDOSTERONE AND OBESITY: WHERE TO LOOK FOR THE KEY TO THERAPY?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ватутин</surname><given-names>Н. Т.</given-names></name><name name-style="western" xml:lang="en"><surname>Vatutin</surname><given-names>N. T.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шевелек</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shevelyok</surname><given-names>A. M.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дегтярева</surname><given-names>А. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Degtiarova</surname><given-names>G. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Телефон: +380 50 928 09 37</p></bio><email xlink:type="simple">an_home@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Донецкий национальный медицинский университет им. М. Горького, г. Донецк, Украина&#13;
&#13;
Институт неотложной и восстановительной хирургии им. В.К. Гусака, г. Донецк, Украина</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M. Gorkiy Donetsk national medical university, Donetsk, Ukraine&#13;
&#13;
V.K.Gusak Institute of emergency and reconstructive surgery, Donetsk, Ukraine</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Донецкий национальный медицинский университет им. М. Горького, г. Донецк, Украина</institution><country>Россия</country></aff><aff xml:lang="en"><institution>M. Gorkiy Donetsk national medical university, Donetsk, Ukraine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>31</day><month>08</month><year>2016</year></pub-date><volume>6</volume><issue>4</issue><fpage>21</fpage><lpage>29</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ватутин Н.Т., Шевелек А.Н., Дегтярева А.Э., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Ватутин Н.Т., Шевелек А.Н., Дегтярева А.Э.</copyright-holder><copyright-holder xml:lang="en">Vatutin N.T., Shevelyok A.M., Degtiarova G.E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/549">https://www.medarhive.ru/jour/article/view/549</self-uri><abstract><p>Длительное время жировая ткань считалась гормонально неактивным «хранилищем» триглицеридов. На сегодняшний день накоплено достаточно доказательств в пользу того, что жировая ткань, помимо основного источника энергии, является активным эндокринным органом, играющим ключевую роль в поддержании гомеостаза и участвующим в патогенезе множества заболеваний. Ее избыток сопровождается гиперактивацией тканевой РААС, усилением локального и системного синтеза альдостерона и возникновением вторичного альдостеронизма. Альдостерон, в свою очередь, оказывает прямое воздействие на жировую ткань через большое количество МКР, экспрессированных на поверхности адипоцитов, что приводит к ускорению созревания последних и дальнейшему увеличению количества жировой ткани. Попадая в системный кровоток и воздействуя на другие органы, избыток этого гормона способствует развитию инсулинорезистентности, атеросклероза, прогрессированию системных воспалительных реакций. В данной статье проанализирована роль альдостерона в возникновении и прогрессировании всех основных компонентов метаболического синдрома: ожирения, АГ, нарушения углеводного обмена и дислипидемии. Рассмотрена возможность применения селективных и неселективных антагонистов минералокортикоидных рецепторов в комплексном лечении больных с ожирением, использование которых, возможно, станет ключом к предупреждению ассоциированных с ним осложнений.</p></abstract><trans-abstract xml:lang="en"><p>For a long period of time adipose tissue was regarded as nonfunctioning ‘store’ of triglycerides. In our day and age there are enough evidence which confirm that, beside being a main source of energy, adipose tissue is an active endocrine organ, which plays a crucial role in maintaining homeostasis and taking part in the pathogenesis of many diseases. It`s excess is accompanied with hyperactivation of local renin-angiotensin-aldosterone system, increasing of local and systemic concentration of aldosterone and eventually leads to formation of secondary hyperaldosteronism. Aldosterone, in turn, has a direct effect on adipose tissue through a large number of mineralocorticoid receptors expressed on the surface of adipocytes. This leads to an accelerated maturation of the adipose cells and further increase in the amount of adipose tissue Reaching systemic circulation and influencing other organs, the excess of the hormone leads to the insulin resistance, atherosclerosis and progression of systemic inflammatory reactions. The role of aldosterone in the onset and progression of all components of metabolic syndrome — obesity arterial hypertension, glucose metabolism and dyslipidemia — are analyzed in this article. The possibility of usage of selective and non-selective antagonists of the mineralocorticoid receptor in complex treatment of patients with obesity is discussed. Who knows, maybe their usе will become a key to the preventing of the obesity-associated complications.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ожирение</kwd><kwd>метаболический синдром</kwd><kwd>альдостерон</kwd><kwd>адипоцитокины</kwd><kwd>тканевая ренин-ангиотензин-альдостероновая система</kwd><kwd>вторичный гиперальдостеронизм</kwd><kwd>инсулинорезистентность</kwd><kwd>дислипидемия</kwd><kwd>артериальная гипертензия</kwd><kwd>антагонисты минералокортикоидных рецепторов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obesity</kwd><kwd>metabolic syndrome</kwd><kwd>aldosterone</kwd><kwd>adipocytokines</kwd><kwd>local renin-angiotensin-aldosterone system</kwd><kwd>secondary hyperaldosteronism</kwd><kwd>insulin resistance</kwd><kwd>dyslipidemia</kwd><kwd>hypertension</kwd><kwd>mineralocorticoid receptor antagonists</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Анисимова Е.В., Козлова И.В., Волков С. В., Мещеряков В.Л. Патология органов пищеварения при ожирении (обзор). Саратовский научно-медицинский журнал. 2011; 7(4): 851-856. Anisimova E.V. Kozlova I.V. Volkov S.V., Mesheryakov V.L. Pathology of the digestive system in obesity. Saratov Journal of Medical Scientific Research. 2011; 7 (4): 851-856 (in Russian).</mixed-citation><mixed-citation xml:lang="en">Анисимова Е.В., Козлова И.В., Волков С. В., Мещеряков В.Л. Патология органов пищеварения при ожирении (обзор). Саратовский научно-медицинский журнал. 2011; 7(4): 851-856. Anisimova E.V. Kozlova I.V. Volkov S.V., Mesheryakov V.L. Pathology of the digestive system in obesity. Saratov Journal of Medical Scientific Research. 2011; 7 (4): 851-856.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ватутин Н.Т., Шевелёк А.Н., Дегтярева А.Э. и др. Роль гиперальдостеронизма и перспективы применения антагонистов альдостерона при резистентной артериальной гипертензии. Журнал национальной академии медицинских наук. 2014; 20(1): 43-52. Vatutin N.T., Shevelok A.N., Degtiarova G.E. et.al. The role of hyperaldosteronism and prospects of aldosterone antagonists in the treatment of resistant hypertension. Journal of National Academy of Medical Sciences. 2014; 20 (1): 43-52 (in Russian).</mixed-citation><mixed-citation xml:lang="en">Ватутин Н.Т., Шевелёк А.Н., Дегтярева А.Э. и др. Роль гиперальдостеронизма и перспективы применения антагонистов альдостерона при резистентной артериальной гипертензии. Журнал национальной академии медицинских наук. 2014; 20(1): 43-52. Vatutin N.T., Shevelok A.N., Degtiarova G.E. et.al. The role of hyperaldosteronism and prospects of aldosterone antagonists in the treatment of resistant hypertension. Journal of National Academy of Medical Sciences. 2014; 20 (1): 43-52.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ивлева А.Я., Старостина Е.Г. Ожирение — проблема медицинская, а не косметическая. Ожирение и метаболизм. 2010; 3: 15-19. Ivleva A.Ya., Starostina E.G. Obesity is a medical problem but not a cosmetic one. Obesity and Metabolism. 2010; 3: 15- 19 (in Russian).</mixed-citation><mixed-citation xml:lang="en">Ивлева А.Я., Старостина Е.Г. Ожирение – проблема медицинская, а не косметическая. Ожирение и метаболизм. 2010; 3: 15-19. Ivleva A.Ya., Starostina E.G. Obesity is a medical problem but not a cosmetic one. Obesity and Metabolism. 2010; 3: 15-19.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ройтберг Г.Е. Метаболический синдром. Москва. «МЕДпресс-информ». 2007; 20 с. Roitberg G.E. Metabolic syndrome. Moscow, “MEDpress inform”, 2007; 224 p. (in Russian).</mixed-citation><mixed-citation xml:lang="en">Ройтберг Г.Е. Метаболический синдром. Москва. «МЕДпресс-информ». 2007; 20 с.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Теряева Н.Б. Адипокины: регуляция энергетического метаболизма и патогенез сердечно-сосудистых заболеваний. Креативная кардиология. 2007; 1–2: 20-25. Teryaeva N.B. Adipokines: regulation of energy metabolism and the pathogenesis of cardiovascular diseases. Creative cardiology. 2007; 1-2: 20-25 (in Russian).</mixed-citation><mixed-citation xml:lang="en">Roitberg G.E. Metabolic syndrome. Moscow, "MEDpress inform", 2007; 224 p.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чубриева С.Ю., Глухов Н.В., Зайчик А.М. Жировая ткань как эндокринный регулятор (обзор литературы). Вестник Санкт- Петербургского университета. 2008; 1: 32-42. Chubrieva S.Yu., Glukhov N.V., Zaichik A.M. Adipose tissue as an endocrine regulator. Vestnik of St. Petersburg University. 2008; 1: 32-42 (in Russian).</mixed-citation><mixed-citation xml:lang="en">Теряева Н.Б. Адипокины: регуляция энергетического метаболизма и патогенез сердечно-сосудистых заболеваний. Креативная кардиология. 2007; 1–2: 20-25. Teryaeva N.B. Adipokines: regulation of energy metabolism and the pathogenesis of cardiovascular diseases. Creative cardiology. 2007; 1-2: 20-25.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Шестакова М.В. Активность ренин-ангиотензиновой системы жировой ткани: метаболические эффекты блокады РАС. Ожирение и метаболизм. 2011; 1: 21-25. Shestakoba M.V. The activity of the renin-angiotensin system of adipose tissue: the metabolic effects of RAS blockade. Obesity and Metabolism. 2011; 1: 21-25 (in Russian).</mixed-citation><mixed-citation xml:lang="en">Чубриева С.Ю., Глухов Н.В., Зайчик А.М. Жировая ткань как эндокринный регулятор (обзор литературы). Вестник санкт-петербургского университета. 2008; 1: 32-42.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Andronico G., Cottone S., Mangano M.T. et. al. Insulin, renin-aldosterone system and blood pressure in obese people. In J. Obes. Relat. Metab. Disord. 2001; 25: 239–242.</mixed-citation><mixed-citation xml:lang="en">Chubrieva S.Yu., Glukhov N.V., Zaichik A.M. Adipose tissue as an endocrine regulator. Vestnik of St. Petersburg University. 2008; 1: 32-42.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bomback A.S., Muskala P., Bald E. et.al. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin. Nephrol. 2009; 72(6): 449-456.</mixed-citation><mixed-citation xml:lang="en">Шестакова М.В. Активность ренин-ангиотензиновой системы жировой ткани: метаболические эффекты блокады РАС. Ожирение и метаболизм. 2011; 1: 21-25.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Briones A.M., Nguyen Dinh Cat. A., Callera G.E. et.al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus- associated obesity and vascular dysfunction. Hypertension. 2012; 59(5): 1069-1078.</mixed-citation><mixed-citation xml:lang="en">Shestakoba M.V. The activity of the renin-angiotensin system of adipose tissue: the  metabolic effects of RAS blockade. Obesity and Metabolism. 2011; 1: 21-25.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Brown C.D., Higgins M., Donato K.A. et.al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000; 8(9): 605-619.</mixed-citation><mixed-citation xml:lang="en">Andronico G., Cottone S., Mangano M.T. et. al. Insulin, renin-aldosterone system  and blood pressure in obese people. In J. Obes. Relat. Metab. Disord. 2001; 25: 239–242.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Calhoun D.A., Sharma K. The role of aldosteronism in causing obesityrelated cardiovascular risk. Cardiol. Clin. 2010; 28(3): 517-527.</mixed-citation><mixed-citation xml:lang="en">Bomback A.S., Muskala P., Bald E. et.al. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage. Clin. Nephrol. 2009; 72(6): 449-456.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Catena C., Lapenna R,, Baroselli S. et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 2006; 91: 3457–3463.</mixed-citation><mixed-citation xml:lang="en">Briones A.M., Nguyen Dinh Cat. A., Callera G.E. et.al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012; 59(5): 1069-1078.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Conn J.W., Knopf R.F., Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am. J. Surg. 1964; 107: 159–172.</mixed-citation><mixed-citation xml:lang="en">Brown C.D., Higgins M., Donato K.A. et.al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000; 8(9): 605-619.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Corry D.B., Tuck M.L. The effect of aldosterone on glucose metabolism. Curr. Hypertens. Rep. 2003; 5: 106–109.</mixed-citation><mixed-citation xml:lang="en">Calhoun D.A., Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol. Clin. 2010; 28(3): 517-527.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Davies J.I., Band M., Morris A et.al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004; 47(10): 1687-1694.</mixed-citation><mixed-citation xml:lang="en">Catena C., Lapenna R,, Baroselli S. et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 2006; 91: 3457–3463.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ehrhart-Bornstein M., Arakelyan K., Krug A.W. et.al. Fat cells may be the obesity- hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004; 30(4): 865-870.</mixed-citation><mixed-citation xml:lang="en">Conn J.W., Knopf R.F., Nesbit R.M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am. J. Surg. 1964; 107: 159–172.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Even S.E., Dulak-Lis M.G., Touyz R.M. et.al. Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR). Horm. Mol. Biol. Clin. Investig. 2014; 19(2): 89-101.</mixed-citation><mixed-citation xml:lang="en">Corry D.B., Tuck M.L. The effect of aldosterone on glucose metabolism. Curr. Hypertens. Rep. 2003; 5: 106–109.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ezequiel D.G., Paula R.B., Lovisi J.C. et.al. Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome. J. Bras. Nefrol. 2013; 35(1): 69-72.</mixed-citation><mixed-citation xml:lang="en">Davies J.I., Band M., Morris A et.al. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004; 47(10): 1687-1694.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Fallo F., Della Mea P., Sonino N. et.al. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens. 2007; 20(8): 855-861.</mixed-citation><mixed-citation xml:lang="en">Ehrhart-Bornstein M., Arakelyan K., Krug A.W. et.al. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004; 30(4): 865-870.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Feliciano Pereira P., Eloiza Priore S., Bressan J. Aldosterone: a cardiometabolic risk hormone? Nutr. Hosp. 2014; 30: 1191-1202.</mixed-citation><mixed-citation xml:lang="en">Even S.E., Dulak-Lis M.G., Touyz R.M. et.al. Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR/GR). Horm. Mol. Biol. Clin. Investig. 2014; 19(2): 89-101.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Gaillard S., Gaillard R. Adipose tissue as an endocrine organ. Obesity &amp; Metabolism. 2007; 3: 191–205.</mixed-citation><mixed-citation xml:lang="en">Ezequiel D.G., Paula R.B., Lovisi J.C. et.al. Spironolactone reduces blood pressure and albuminuria of obese hypertensive patients with metabolic syndrome. J. Bras. Nefrol. 2013; 35(1): 69-72.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Garg R., Kneen L., Williams G.H. et.al. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab. 2014; 16(3): 268-272.</mixed-citation><mixed-citation xml:lang="en">Fallo F., Della Mea P., Sonino N. et.al. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens. 2007; 20(8): 855-861.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Goodfriend T.L., Egan B., Stepniakowski K. et.al. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995; 25: 30-36.</mixed-citation><mixed-citation xml:lang="en">Feliciano Pereira P., Eloiza Priore S., Bressan J. Aldosterone: a cardiometabolic risk hormone? Nutr. Hosp. 2014; 30: 1191-1202.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Goodfriend T.L., Kelley D.E., Goodpaster B.H. et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 1999; 7: 355–362.</mixed-citation><mixed-citation xml:lang="en">Gaillard S., Gaillard R. Adipose tissue as an endocrine organ. Obesity &amp; Metabolism. 2007; 3: 191–205.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Guzik T.J., Marvar P.J., Czesnikiewicz-Guzik M. et.al. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J. Physiol. Pharmacol. 2007; 58: 591–610.</mixed-citation><mixed-citation xml:lang="en">Garg R., Kneen L., Williams G.H. et.al. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab. 2014; 16(3): 268-272.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hayden M.R., Sowers J.R. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. J. Cardiometab. Syndr. 2008; 3(3): 129-131.</mixed-citation><mixed-citation xml:lang="en">Goodfriend T.L., Egan B., Stepniakowski K. et.al. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension. 1995; 25: 30-36.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Hirata A., Maeda N., Hiuge A. et. al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovascular Research. 2009; 84: 164–172.</mixed-citation><mixed-citation xml:lang="en">Goodfriend T.L., Kelley D.E., Goodpaster B.H. et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 1999; 7: 355–362.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Hitomi, H., Kiyomoto H., Nishiyama A., et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007; 50: 750–755.</mixed-citation><mixed-citation xml:lang="en">Guzik T.J., Marvar P.J., Czesnikiewicz-Guzik M. et.al. Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. J. Physiol. Pharmacol. 2007; 58: 591–610.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Iacobellis G., Petramala L., Cotesta D. et.al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J. Clin. Endocrinol. Metab. 2010; 95: 2391–2398.</mixed-citation><mixed-citation xml:lang="en">Hayden M.R., Sowers J.R. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus. J. Cardiometab. Syndr. 2008; 3(3): 129-131.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon J.H., Kim K.Y., Kim J.H. et.al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008; 22(5): 1502-1511.</mixed-citation><mixed-citation xml:lang="en">Hirata A., Maeda N., Hiuge A. et. al. Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovascular Research. 2009; 84: 164–172.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Kang Y.S. Obesity associated hypertension: new insights into mechanism. Electrolyte Blood Press. 2013; 11(2): 46-52.</mixed-citation><mixed-citation xml:lang="en">Hitomi, H., Kiyomoto H., Nishiyama A., et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007; 50: 750–755.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kathiresan S., Larson M.G., Benjamin E.J. et. al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am. J. Hypertens. 2005; 18: 657–665.</mixed-citation><mixed-citation xml:lang="en">Iacobellis G., Petramala L., Cotesta D. et.al. Adipokines and cardiometabolic profile in primary hyperaldosteronism. J. Clin. Endocrinol. Metab. 2010; 95: 2391–2398.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kidambi S., Kotchen J., Grim C. et.al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007; 49: 704–711.</mixed-citation><mixed-citation xml:lang="en">Jeon J.H., Kim K.Y., Kim J.H. et.al. A novel adipokine CTRP1 stimulates aldosterone production. FASEB J. 2008; 22(5): 1502-1511.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Krug A.W., Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additionalrisk factor? Hypertension. 2008; 51(5): 1252-1258.</mixed-citation><mixed-citation xml:lang="en">Kang Y.S. Obesity associated hypertension: new insights into mechanism. Electrolyte Blood Press. 2013; 11(2): 46-52.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Lamounier-Zepter V., Ehrhart-Bornstein M,, Bornstein S.R. Mineralocorticoid-stimulating activity of adipose tissue. Best. Pract. Res. Clin. Endocrinol. Metab. 2005; 19: 567–575.</mixed-citation><mixed-citation xml:lang="en">Kathiresan S., Larson M.G., Benjamin E.J. et. al. Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. Am. J. Hypertens. 2005; 18: 657–665.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Lastra G., Whaley-Connell A., Manrique C. et.al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulinstimulated glucose transport in skeletal muscle in the TG (mRen2)27 rat. Am. J. Physiol. Endocrinol. Metab. 2008; 295(1): 110-116.</mixed-citation><mixed-citation xml:lang="en">Kidambi S., Kotchen J., Grim C. et.al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007; 49: 704–711.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Luther J.M. Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014; 91: 54-60.</mixed-citation><mixed-citation xml:lang="en">Krug A.W., Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additionalrisk factor? Hypertension. 2008; 51(5): 1252-1258.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Matsuda M., Shimomura I. Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk. Horm Mol Biol Clin Investig. 2014; 19(2): 75-88.</mixed-citation><mixed-citation xml:lang="en">Lamounier-Zepter V., Ehrhart-Bornstein M,, Bornstein S.R. Mineralocorticoid-stimulating activity of adipose tissue. Best. Pract. Res. Clin. Endocrinol. Metab. 2005; 19: 567–575.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Paula R.B., Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004; 43(1): 41-47.</mixed-citation><mixed-citation xml:lang="en">Lastra G., Whaley-Connell A., Manrique C. et.al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG (mRen2)27 rat. Am. J. Physiol. Endocrinol. Metab. 2008; 295(1): 110-116.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Reincke M., Meisinger C., Holle R. et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm. Metab. Res. 2010; 42: 435–439.</mixed-citation><mixed-citation xml:lang="en">Luther J.M. Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014; 91: 54-60.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Salmenniemi U., Ruotsalainen E., Pihlajamaki J. et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004; 110: 3842– 3848.</mixed-citation><mixed-citation xml:lang="en">Matsuda M., Shimomura I. Roles of oxidative stress, adiponectin, and nuclear hormone receptors in obesity-associated insulin resistance and cardiovascular risk. Horm Mol Biol Clin Investig. 2014; 19(2): 75-88.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Sarafidis P.A., Bakris G.L. Review: Insulin and endothelin: an interplay contributing to hypertension development? J. Clin. Endocrinol. Metab. 2007; 92: 379–385.</mixed-citation><mixed-citation xml:lang="en">Paula R.B., Silva A.A., Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension. 2004; 43(1): 41-47.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Savoia C., Touyz R.M., Amiri F. et.al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008; 51: 432– 439.</mixed-citation><mixed-citation xml:lang="en">Reincke M., Meisinger C., Holle R. et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry. Horm. Metab. Res. 2010; 42: 435–439.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Sindelka G., Widimský J., Haas T., et. al. Insulin action in primary aldosteronism before and after surgical or pharmacological treatment. Exp. Clin. Endocrinol. Diabetes. 2000; 108: 21–25.</mixed-citation><mixed-citation xml:lang="en">Salmenniemi U., Ruotsalainen E., Pihlajamaki J. et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004; 110: 3842–3848.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Souza F., Muxfeldt E., Fiszman R. et.al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010; 55(1): 147-152.</mixed-citation><mixed-citation xml:lang="en">Sarafidis P.A., Bakris G.L. Review: Insulin and endothelin: an interplay contributing to hypertension development? J. Clin. Endocrinol. Metab. 2007; 92: 379–385.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Stiefel P., Vallejo-Vaz A.J., Garc.ıaMorillo S. et.al. Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome. Int. J. Hypertens. 2011;2011:685238. doi: 10.4061/2011/685238</mixed-citation><mixed-citation xml:lang="en">Savoia C., Touyz R.M., Amiri F. et.al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008; 51: 432– 439.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Vaněčková I., Maletínská L., Behuliak M. et.al. Obesity-related hypertension: possible pathophysiological mechanisms. J. Endocrinol. 2014; 223(3): 63-78.</mixed-citation><mixed-citation xml:lang="en">Sindelka G., Widimský J., Haas T., et. al. Insulin action in primary aldosteronism before and after surgical or pharmacological treatment. Exp. Clin. Endocrinol. Diabetes. 2000; 108: 21–25.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Vasan R.S., Evans J.C., Larson M.G. et.al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004; 351: 33– 41.</mixed-citation><mixed-citation xml:lang="en">Souza F., Muxfeldt E., Fiszman R. et.al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010; 55(1): 147-152.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Wang P., Mariman E., Renes J., Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell Physiol. 2008; 216(1): 3-13.</mixed-citation><mixed-citation xml:lang="en">Stiefel P., Vallejo-Vaz A.J., Garc.ıaMorillo S. et.al. Role of the Renin-Angiotensin System and Aldosterone on Cardiometabolic Syndrome. Int. J. Hypertens.  2011;2011:685238. doi: 10.4061/2011/685238</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010; 52(5): 401–409.</mixed-citation><mixed-citation xml:lang="en">Vaněčková I., Maletínská L., Behuliak M. et.al. Obesity-related hypertension: possible pathophysiological mechanisms. J. Endocrinol. 2014; 223(3): 63-78.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaji M., Tsutamoto T., Kawahara C. et.al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. Am. Heart J. 2010; 160(5): 915-921.</mixed-citation><mixed-citation xml:lang="en">Vasan R.S., Evans J.C., Larson M.G. et.al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 2004; 351: 33– 41.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Yamashita R., Kikuchi T., Mori Y. et. al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr. J. 2004; 51: 243–251.</mixed-citation><mixed-citation xml:lang="en">Wang P., Mariman E., Renes J., Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J. Cell Physiol. 2008; 216(1): 3-13.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010; 52(5): 401–409.</mixed-citation><mixed-citation xml:lang="en">Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog. Cardiovasc. Dis. 2010; 52(5): 401–409.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaji M., Tsutamoto T., Kawahara C. et.al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. Am. Heart J. 2010; 160(5): 915-921.</mixed-citation><mixed-citation xml:lang="en">Yamaji M., Tsutamoto T., Kawahara C. et.al. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. Am. Heart J. 2010; 160(5): 915-921.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Yamashita R., Kikuchi T., Mori Y. et. al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of  the protein kinase B cascade. Endocr. J. 2004; 51: 243–251.</mixed-citation><mixed-citation xml:lang="en">Yamashita R., Kikuchi T., Mori Y. et. al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of  the protein kinase B cascade. Endocr. J. 2004; 51: 243–251.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
